UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B

Journal of viral hepatitis, 2009-01, Vol.16 (1), p.36-44

2009

Volltextzugriff (PDF)

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.532-539

2014

Volltextzugriff (PDF)

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Alimentary pharmacology & therapeutics, 2010-12, Vol.32 (11‐12), p.1323-1331

2010

Volltextzugriff (PDF)

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations

Alimentary pharmacology & therapeutics, 2014-04, Vol.39 (8), p.883-893

2014

Volltextzugriff (PDF)

Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B

Gut, 2009-01, Vol.58 (1), p.111-117

2009

Volltextzugriff (PDF)

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years

Alimentary pharmacology & therapeutics, 2012-06, Vol.35 (11), p.1326-1335

2012

Volltextzugriff (PDF)

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.731-740

2015

Volltextzugriff (PDF)

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1057-1066

2012

Volltextzugriff (PDF)

Serum interferon‐inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (1), p.145-153

2016

Volltextzugriff (PDF)

Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels

Alimentary pharmacology & therapeutics, 2009-02, Vol.29 (4), p.387-396

2009

Volltextzugriff (PDF)

Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.716-726

2014

Volltextzugriff (PDF)

Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B

Alimentary pharmacology & therapeutics, 2007-04, Vol.25 (8), p.891-898

2007

Volltextzugriff (PDF)

A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China

Journal of viral hepatitis, 2008-06, Vol.15 (6), p.449-458

2008

Volltextzugriff (PDF)

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

Gut, 2010-07, Vol.59 (7), p.969-974

2010

Volltextzugriff (PDF)

Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease

Gut, 2011-12, Vol.60 (12), p.1721-1727

2011

Volltextzugriff (PDF)

High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis

Gut, 2011-06, Vol.60 (6), p.829-836

2011

Volltextzugriff (PDF)

Double‐blinded placebo‐controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B

Alimentary pharmacology & therapeutics, 2003-08, Vol.18 (3), p.339-345

2003

Volltextzugriff (PDF)

Metabolic syndrome delays HB eAg seroclearance in Chinese patients with hepatitis B

Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (6), p.716-726

2014

Volltextzugriff (PDF)

PNPLA 3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.532-539

2014

Volltextzugriff (PDF)

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HB e A g‐seroconversion in chronic hepatitis B patients at 3 years

Alimentary pharmacology & therapeutics, 2012-06, Vol.35 (11), p.1326-1335

2012

Volltextzugriff (PDF)

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B

Antiviral therapy, 2008-01, Vol.13 (4), p.571-579

2008

Volltextzugriff (PDF)

Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon a2a (40 kDa; PEGASYS+)

Antiviral therapy, 2008-01, Vol.13 (4), p.555-562

2008

Volltextzugriff (PDF)

Virodynamic predictors of response to pegylated interfered and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B

Antiviral therapy, 2008-01, Vol.13 (8), p.1029-1037

2008

Volltextzugriff (PDF)

Association of genetic variations with NAFLD in lean individuals

Liver international, 2022-01, Vol.42 (1), p.149-160

2022

Volltextzugriff (PDF)

Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study

Journal of hepatology, 2014-04, Vol.60 (4), p.809-815

2014

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(45)
Humans
(43)
Female
(33)
Male
(32)
Biological And Medical Sciences
(31)
Medical Sciences
(30)
Adult
(28)
Middle Aged
(27)
Gastroenterology & Hepatology
(26)
Infectious Diseases
(20)
Gastroenterology. Liver. Pancreas. Abdomen
(15)
Human Viral Diseases
(14)
Pharmacology & Pharmacy
(14)
Viral Diseases
(14)
Viral Hepatitis
(14)
Hepatitis B E Antigens - Blood
(11)
Liver. Biliary Tract. Portal Circulation. Exocrine Pancreas
(11)
Other Diseases. Semiology
(11)
Treatment Outcome
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B

PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations

Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

Serum interferon‐inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B

Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels

Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B

Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B

A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease

High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis

Double‐blinded placebo‐controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B

Metabolic syndrome delays HB eAg seroclearance in Chinese patients with hepatitis B

PNPLA 3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HB e A g‐seroconversion in chronic hepatitis B patients at 3 years

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B

Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon a2a (40 kDa; PEGASYS+)

Virodynamic predictors of response to pegylated interfered and lamivudine combination treatment of hepatitis B e antigen-positive chronic hepatitis B

Association of genetic variations with NAFLD in lean individuals

Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study

Suchergebnisse filtern